How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Three Harvard faculty said they think fears that an artificial intelligence bubble will burst — leading stock prices to collapse in the wake of soaring investments into AI companies — are overblown ...

Dr. Frey is an economist at the University of Oxford and the author of the book “How Progress Ends: Technology, Innovation and the Fate of Nations.” “Bubbles are great. May the bubbles continue,” Eric ...

The valuations of some artificial intelligence companies are approaching those of the dot-com boom. But investors worry that pulling money from today’s market risks future gains. Note: Data is plotted ...

A little over three years ago, Artificial Intelligence technology took off in the public consciousness with OpenAI's public release of ChatGPT. Stock prices continued falling through September 2022 ...

OpenAI CEO Sam Altman's comments helped spark concerns about an AI bubble. Mark Cuban says he doesn't see similarities to the dot-com bubble. There's disagreement, even among business leaders and tech ...